LQDA vs. GKOS, TMDX, IRTC, NARI, BLCO, INSP, SLNO, PRCT, NVST, and LIVN
Should you be buying Liquidia stock or one of its competitors? The main competitors of Liquidia include Glaukos (GKOS), TransMedics Group (TMDX), iRhythm Technologies (IRTC), Inari Medical (NARI), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Soleno Therapeutics (SLNO), PROCEPT BioRobotics (PRCT), Envista (NVST), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.
Liquidia vs.
Glaukos (NYSE:GKOS) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.
In the previous week, Liquidia had 10 more articles in the media than Glaukos. MarketBeat recorded 13 mentions for Liquidia and 3 mentions for Glaukos. Glaukos' average media sentiment score of 0.84 beat Liquidia's score of 0.60 indicating that Glaukos is being referred to more favorably in the media.
Glaukos presently has a consensus target price of $134.67, indicating a potential upside of 40.75%. Liquidia has a consensus target price of $26.67, indicating a potential upside of 78.02%. Given Liquidia's stronger consensus rating and higher probable upside, analysts plainly believe Liquidia is more favorable than Glaukos.
Glaukos has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.
99.0% of Glaukos shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 5.8% of Glaukos shares are owned by company insiders. Comparatively, 26.5% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Glaukos received 238 more outperform votes than Liquidia when rated by MarketBeat users. However, 69.52% of users gave Liquidia an outperform vote while only 65.19% of users gave Glaukos an outperform vote.
Liquidia has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
Glaukos has a net margin of -39.04% compared to Liquidia's net margin of -765.38%. Glaukos' return on equity of -16.53% beat Liquidia's return on equity.
Summary
Liquidia beats Glaukos on 10 of the 19 factors compared between the two stocks.
Get Liquidia News Delivered to You Automatically
Sign up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Liquidia Competitors List
Related Companies and Tools
This page (NASDAQ:LQDA) was last updated on 6/11/2025 by MarketBeat.com Staff
